NRx Pharmaceuticals (NASDAQ:NRXP) Given New $45.00 Price Target at Ascendiant Capital Markets

NRx Pharmaceuticals (NASDAQ:NRXP) had its price objective increased by research analysts at Ascendiant Capital Markets from $44.00 to $45.00 in a note issued to investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

A number of other analysts have also recently weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $19.00 target price on shares of NRx Pharmaceuticals in a research note on Monday, November 25th. EF Hutton Acquisition Co. I upgraded NRx Pharmaceuticals to a “strong-buy” rating in a research note on Monday, October 21st.

NRx Pharmaceuticals Price Performance

Shares of NRXP stock opened at $1.31 on Monday. The stock has a market cap of $15.84 million, a P/E ratio of -0.61 and a beta of 1.27. The stock has a fifty day moving average price of $1.36 and a 200 day moving average price of $2.11. NRx Pharmaceuticals has a one year low of $1.10 and a one year high of $7.33.

Institutional Investors Weigh In On NRx Pharmaceuticals

An institutional investor recently bought a new position in NRx Pharmaceuticals stock. Anson Funds Management LP acquired a new position in shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 142,525 shares of the company’s stock, valued at approximately $241,000. Anson Funds Management LP owned approximately 1.33% of NRx Pharmaceuticals at the end of the most recent quarter. 4.27% of the stock is currently owned by hedge funds and other institutional investors.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.